Because of this predictive potential, TMB is emerging as a prominent independent biomarker for prediction of response to programmed cell death protein 1 (PD-1)/PD-L1 (PDx) pathway inhibitors in multiple cancer types [9], aided by the development of next-generation sequencing. This evidence concerns the gene CD274 and cancer.